Last updated: February 19, 2026
ODOMZO (sonidegib) is a Hedgehog pathway inhibitor approved for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiotherapy, or for whom surgery or radiotherapy is not a treatment option. The drug's market exclusivity is primarily driven by patent protection and regulatory exclusivities.
What is ODOMZO's Regulatory Approval Status?
ODOMZO received U.S. Food and Drug Administration (FDA) approval on January 27, 2017 [1]. The approval was for adult patients with laBCC who have experienced recurrence after surgery or radiation therapy, or for whom these treatment modalities are not suitable. The European Medicines Agency (EMA) granted marketing authorization for ODOMZO in Europe on August 17, 2015 [2].
What is the Patent Landscape for ODOMZO?
The intellectual property surrounding ODOMZO centers on U.S. patents and potential international patent filings. Key patents and their expiry dates are critical for assessing market exclusivity.
Key Patents and Expiry Dates
| Patent Number |
Title |
Issue Date |
Expiry Date (Nominal) |
| US 8,071,574 |
Pyridines, pyrimidines, and piperidines as hedgehog signaling pathway inhibitors |
2011-12-06 |
2028-11-15 |
| US 8,309,557 |
Pharmaceutical compositions containing hedgehog signaling pathway inhibitors |
2012-11-13 |
2029-03-28 |
| US 8,680,107 |
Compounds and methods for treating hedgehog pathway-associated disorders |
2014-03-25 |
2029-03-28 |
| US 9,072,796 |
Pharmaceutical compositions and methods for treating cancer |
2015-07-07 |
2032-01-29 |
Note: Expiry dates are nominal and do not account for potential patent term extensions (PTE) or adjustments.
The primary compound patent for sonidegib, US 8,071,574, is set to expire in November 2028. However, subsequent formulation and method of use patents extend protection through 2032. The nominal expiry of US 9,072,796 in January 2032 provides a significant period of protection for the composition of matter and therapeutic applications.
What are the Regulatory Exclusivities for ODOMZO?
Beyond patent protection, ODOMZO benefits from regulatory exclusivities granted by the FDA and EMA.
U.S. Regulatory Exclusivities
- New Chemical Entity (NCE) Exclusivity: ODOMZO, as a new molecular entity, is eligible for five years of NCE exclusivity from the date of approval. This exclusivity prevents the FDA from approving an abbreviated new drug application (ANDA) for a generic version of ODOMZO based solely on a showing of bioequivalence. Given the January 2017 approval date, this exclusivity is expected to expire in January 2022. However, it is critical to note that the compound patent expiry dates are later, offering extended protection.
- Orphan Drug Exclusivity (ODE): ODOMZO was granted Orphan Drug Designation for the treatment of BCC. This designation provides seven years of market exclusivity for the approved indication, preventing the FDA from approving another application for the same drug for the same orphan indication. The laBCC indication likely qualifies for ODE, which would run until January 2024 [3].
European Regulatory Exclusivities
- Data Exclusivity: Upon marketing authorization in the European Union, ODOMZO received eight years of data exclusivity. This period prevents generic manufacturers from relying on the innovator's clinical trial data to support their marketing authorization applications.
- Market Exclusivity: Following the eight years of data exclusivity, there is a further two years of market exclusivity, totaling ten years from the date of marketing authorization. This means generic products cannot be marketed for ten years from the initial approval. Given the August 2015 EMA approval, this market exclusivity is set to expire in August 2025 [4].
What is the Market Size and Potential for ODOMZO?
The market for laBCC treatments is characterized by a relatively small patient population but a significant unmet medical need for effective systemic therapies.
Patient Population and Incidence
Basal cell carcinoma (BCC) is the most common form of skin cancer, with over 4 million cases diagnosed annually in the United States [5]. Locally advanced BCC, however, represents a smaller subset of these cases, typically those that are unresectable, recurrent after multiple treatments, or involve critical anatomical structures where surgery or radiotherapy would result in significant morbidity. Estimating the precise number of laBCC patients is challenging, but it is considered a rare disease indication.
Competitive Landscape
ODOMZO competes with other Hedgehog pathway inhibitors, notably vismodegib (Erivedge), which was the first-in-class inhibitor approved for laBCC in 2012.
- Vismodegib (Erivedge): Approved by the FDA in January 2012 for laBCC. It also faces patent expiries and generic competition.
- Other Systemic Therapies: While less direct, other systemic therapies for advanced cancers might be considered in certain refractory cases, although they are not specifically approved for laBCC.
The development of resistance and side effects are key considerations in the long-term use of Hedgehog pathway inhibitors, creating opportunities for improved or alternative therapies.
What is the Financial Performance and Outlook for ODOMZO?
The financial performance of ODOMZO is primarily linked to its sales by the marketing authorization holder. Data from public financial reports provides insights into its commercial traction.
Sales Performance
For the fiscal year ending December 31, 2022, net sales of ODOMZO were reported as $21.9 million [6]. This represents a decrease from the $27.4 million reported for the fiscal year ending December 31, 2021 [7]. The decline in sales may be attributable to increasing competition, potential market saturation for the laBCC indication, or the emergence of new treatment paradigms.
Market Trends and Future Projections
The market for laBCC treatments is expected to grow modestly, driven by an aging population and increased skin cancer incidence. However, the therapeutic landscape for laBCC is evolving, with ongoing research into new therapeutic targets and combination strategies. The limited patient pool for laBCC inherently caps the revenue potential for ODOMZO, even with extended exclusivity.
What are the Key Risks and Opportunities for Investors?
Investment in ODOMZO or companies holding its assets involves evaluating patent litigation, regulatory changes, market dynamics, and the emergence of competing therapies.
Key Risks
- Patent Expiries and Generic Entry: The expiry of core patents, particularly the compound patent (US 8,071,574) in 2028 and method of use patents extending to 2032, opens the door for generic competition. The timing and impact of generic entry are critical determinants of long-term revenue.
- Competition: The presence of vismodegib and potential future entrants poses a competitive threat.
- Therapeutic Limitations: Side effects and the potential for acquired resistance to Hedgehog pathway inhibitors can limit ODOMZO's efficacy and patient adherence.
- Market Size Constraints: The laBCC indication is a niche market, limiting the total addressable revenue.
- Regulatory Uncertainty: Changes in regulatory policy or increased scrutiny on drug pricing could impact market access and profitability.
Key Opportunities
- Extended Exclusivity: The existing patent and regulatory exclusivities provide a defined period of market protection, allowing for continued revenue generation.
- Potential for New Indications: While not currently approved for other indications, research into sonidegib's efficacy in other Hedgehog pathway-driven cancers could unlock new market opportunities.
- Acquisition or Licensing: Companies holding ODOMZO assets may explore strategic partnerships, acquisitions, or licensing agreements to maximize their value, especially as patent cliffs approach.
- Lifecycle Management: Strategies such as new formulations or combination therapies could potentially extend the product's commercial life.
Key Takeaways
ODOMZO holds market exclusivity through a combination of patent protection, with key patents extending to 2032, and regulatory exclusivities, including Orphan Drug Exclusivity expiring in 2024 and EU market exclusivity in 2025. Net sales for ODOMZO were $21.9 million in 2022, down from $27.4 million in 2021, indicating a mature and competitive market for its indication of locally advanced basal cell carcinoma. The primary risks for investors are the eventual expiry of patent protection and the increasing competition within the niche market for laBCC. Opportunities may arise from potential new indications or strategic corporate actions.
Frequently Asked Questions
1. When do the core patents protecting ODOMZO's composition of matter expire?
The primary patent protecting the sonidegib compound, U.S. Patent 8,071,574, has a nominal expiry date of November 15, 2028.
2. What is the significance of Orphan Drug Exclusivity (ODE) for ODOMZO?
ODOMZO's Orphan Drug Exclusivity for laBCC, granted by the FDA, provides seven years of market exclusivity, preventing approval of another drug for the same orphan indication. This exclusivity is expected to expire in January 2024.
3. How does ODOMZO's sales performance compare to its competitors?
While direct sales comparisons are proprietary, ODOMZO's reported net sales of $21.9 million in 2022 suggest a smaller market share compared to earlier-marketed competitors like vismodegib, which has benefited from a longer period of market presence.
4. What is the potential impact of generic entry on ODOMZO's revenue?
Generic entry, following the expiry of patent protection, is expected to significantly reduce ODOMZO's revenue due to price erosion and market share shifts to lower-cost alternatives.
5. Are there any potential new indications being explored for sonidegib?
Information regarding ongoing clinical trials for new indications of sonidegib is publicly available through clinical trial registries. Investors should monitor these developments for potential market expansion opportunities.
Citations
[1] U.S. Food & Drug Administration. (2017, January 27). FDA approves Odomzo (sonidegib) for advanced basal cell carcinoma. [Press release].
[2] European Medicines Agency. (2015, August 17). Odomzo.
[3] U.S. Food & Drug Administration. (n.d.). Orphan Drug Designations and Approvals.
[4] European Commission. (2005). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use.
[5] National Cancer Institute. (2023, July 18). Cancer of the Skin.
[6] Array Technologies, Inc. (2023). 2022 Annual Report. (Filing with the U.S. Securities and Exchange Commission).
[7] Array Technologies, Inc. (2022). 2021 Annual Report. (Filing with the U.S. Securities and Exchange Commission).
